Tirzepatide
Also referenced as: Mounjaro, Zepbound, GIP/GLP-1 co-agonist
A dual GIP and GLP-1 receptor agonist that produced the largest weight reductions seen in a completed obesity phase 3 programme at the time of publication.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
Approved for type 2 diabetes and, separately, for chronic weight management and obstructive sleep apnoea in adults with obesity. Research-use-only material is not the approved medicine.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- September 1, 2026
Overview
Tirzepatide activates two incretin receptors rather than one: the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. The clinical interest is whether combined signalling improves metabolic outcomes beyond GLP-1 alone.
It is a fully developed pharmaceutical with published phase 3 data, not an experimental research compound, although it is frequently discussed alongside them.
Why It's Being Studied
- Glycaemic control and weight reduction in type 2 diabetes.
- Weight management in obesity without diabetes.
- Sleep apnoea severity, heart failure with preserved ejection fraction and hepatic steatosis.
Mechanism of Action
It copies two gut hormones at once, both of which influence insulin release, appetite and how the body handles fat and sugar.
Tirzepatide is a 39-amino-acid synthetic peptide based on the native GIP sequence, modified with a C20 fatty diacid moiety for albumin binding and once-weekly kinetics. It is an unbalanced agonist with greater affinity for GIP than GLP-1 receptors. Proposed additive mechanisms include GIP-mediated effects on adipose tissue lipid handling and central appetite pathways alongside classical GLP-1 signalling.
Research Areas & Routes Studied
- Body weight
- Glycaemic control
- Obstructive sleep apnoea
- Hepatic steatosis
- Heart failure
- Subcutaneous injection
Evidence Summary
Large randomised phase 3 programmes in diabetes and obesity with published outcomes and approved labels.
Human clinical evidence
- SURMOUNT-1 reported mean weight reduction of roughly 15–21% across doses over 72 weeks versus about 3% with placebo.
- The SURPASS programme reported HbA1c reductions versus active comparators including semaglutide 1 mg.
Clinical trials
- Ongoing trials in cardiovascular outcomes, sleep apnoea and liver disease.
Anecdotal / community information
- Widely discussed online, often using unverified research-use-only material. Such reports say nothing reliable about identity, purity or dose.
Reported Adverse Events in Research
- Gastrointestinal effects dominate: nausea, diarrhoea, vomiting, constipation.
- Injection-site reactions, hypoglycaemia when combined with insulin or sulfonylureas.
- Boxed warning for thyroid C-cell tumours on US labels; gallbladder and pancreatitis warnings.
Limitations of Current Evidence
- Head-to-head data against newer multi-agonists remain limited.
- Discontinuation is followed by substantial weight regain in published extension data.
Documented Research Protocols
Tirzepatide weekly — approved escalation schedule
Summarise the escalation schedule used in the SURMOUNT programme and described in approved labelling.
View documented protocol
Why It Is Used
- Metabolic Health
Weight Loss and Liver Fat
The most common reason people look at peptides at all: sustained appetite reduction, and what trials report about liver fat alongside it.
Read the case study
Research References
- Randomised controlled trial2022
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Jastreboff AM, et al. · New England Journal of Medicine- Population
- 2,539 adults with obesity or overweight with comorbidity, without diabetes
- Main finding
- Dose-dependent mean weight reduction substantially greater than placebo at 72 weeks.
- Limitations
- Excluded diabetes; intensive lifestyle counselling in all arms.
- Prescribing label
Tirzepatide prescribing information
- Regulatory document
Registered tirzepatide trials